4.66
+0.43(+10.17%)
Currency In USD
| Previous Close | 4.23 |
| Open | 4.24 |
| Day High | 4.8 |
| Day Low | 4.15 |
| 52-Week High | 6.3 |
| 52-Week Low | 2.2 |
| Volume | 567,240 |
| Average Volume | 305,589 |
| Market Cap | 263.12M |
| PE | -2.59 |
| EPS | -1.8 |
| Moving Average 50 Days | 3.27 |
| Moving Average 200 Days | 3.34 |
| Change | 0.43 |
If you invested $1000 in Orchestra BioMed Holdings, Inc. (OBIO) since IPO date, it would be worth $408.77 as of November 19, 2025 at a share price of $4.66. Whereas If you bought $1000 worth of Orchestra BioMed Holdings, Inc. (OBIO) shares 3 years ago, it would be worth $473.1 as of November 19, 2025 at a share price of $4.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Orchestra BioMed to Host Business Update Call on November 12, 2025
GlobeNewswire Inc.
Nov 03, 2025 1:00 PM GMT
NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a total of $30 million to Orchestra BioMedOrchestra BioMed retains all development and distribution rights to V
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
GlobeNewswire Inc.
Oct 27, 2025 1:00 PM GMT
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFRTM”)The Virtue Trial is th